On August 14, US Physical Therapy (NYSE:USPH) announced that Nchacha Etta will become the company’s Executive Vice President and Chief Financial Officer, effective September 1. The move closes out a search that began after Jason Curtis stepped in as interim CFO on April 24, and it arrives as the outpatient physical therapy operator works through a run of acquisitions, hospital partnerships, and a reaffirmed 2026 earnings outlook.
A Résumé Built For Scale
Etta’s path to USPH runs through some of the largest names in healthcare and consumer goods. He most recently served as Executive Vice President and Chief Financial Officer of Omnicell (NASDAQ:OMCL) from 2023 to 2025, overseeing global finance, information technology, and investor relations at the healthcare technology company. Before that, he was Senior Vice President and Chief Financial Officer of Essilor of America, a subsidiary of EssilorLuxottica, from 2019 through 2022, and Worldwide Vice President and Chief Financial Officer of Johnson & Johnson Vision from 2015 to 2019. He spent the nine years before that in senior finance roles at The Coca-Cola Company, with earlier stops at Microsoft, Eli Lilly, and The Carlyle Group.
Etta holds a Bachelor of Science in Accounting from George Mason University and an MBA in Finance from Howard University, and he has sat on the board of KBR since 2024, where he serves on the Audit Committee and the Sustainability, Technology and Cybersecurity Committee. He steps into the CFO seat at a company that grew total net revenue 8.5% to $214.1 million in the second quarter of 2026, closed three acquisitions this year for a combined $37.6 million, and reaffirmed full-year adjusted EBITDA guidance of $102 million to $106 million. CEO Chris Reading called the hire the result of “a very comprehensive search” and pointed to Etta’s track record as a public company CFO.
Where The Numbers Get Tighter
The backdrop Etta is inheriting isn’t all momentum. Net income attributable to USPH shareholders fell to $9.9 million in the second quarter of 2026 from $12.4 million a year earlier, with EPS dropping to $0.25 from $0.58. Physical therapy margin slipped to 19.5% from 21.2%, a decline the company attributed partly to about 100 basis points of pressure from company-provided health benefit costs. That pattern held through the first half of the year, with six-month net income down to $14.9 million from $22.3 million and EPS falling to $0.13 from $1.38.
The balance sheet moved too. Cash and cash equivalents dropped to $24.9 million as of June 30, from $35.6 million at the end of 2025, while borrowings under the company’s credit facility climbed to $221 million from $161.8 million. That followed an April 14 refinancing into a $450 million, five-year credit facility, replacing a $325 million facility that wasn’t due until June 17, 2027.
Skepticism Still Outpaces Conviction
Hedge fund ownership of US Physical Therapy ticked up to 14 funds from 13 the prior quarter, a modest gain rather than a rush of new conviction. Short interest sits at 10.30% of the float, a level that points to a real bear camp still positioned against the stock. The forward price-to-earnings ratio of 25.84, as of September 11, shows that the market is still paying up for the name even as short sellers stay crowded in, a split that suggests investors haven’t settled on which trend, the margin pressure or the growth pipeline, will win out.
A New CFO Inherits A Split Story
USPH is handing the CFO role to an executive with fifteen-plus years running finance at global companies, right as its own margins compress and its debt load grows alongside a busy acquisition and hospital-affiliation pipeline. For the growth side of the story to win out, the integration of 39 remaining hospital-affiliated clinics and the recently expanded credit facility need to translate into the accelerating back-half EBITDA growth management has promised. For the caution to hold, the health benefit cost pressure and shrinking per-share earnings would need to persist even as revenue keeps climbing.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
Hedge Fund Resource Center